Evidence map›Paper›PMID 32812025›Full record

Trial reportThe Journal of antimicrobial chemotherapy2020

Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.

Hamideh Abbaspour Kasgari, Siavash Moradi, Amir Mohammad Shabani, Farhang Babamahmoodi, Ali Reza Davoudi Badabi, Lotfollah Davoudi, Ahmad Alikhani, Akbar Hedayatizadeh Omran, Majid Saeedi, Shahin Merat and 6 more

Open access · bronzeAbstract readComparative StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of antimicrobial chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 14 pooled it
2.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 14 syntheses or guidelines pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2021
    Pooled it
  7. Pooled it
  8. Clinical efficacy of antiviral agents against coronavirus disease 2019: A systematic review of randomized controlled trials.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2021
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Current evidence for COVID-19 therapies: a systematic literature review.European respiratory review : an official journal of the European Respiratory Society · 2021
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Antivirals in COVID-19: A Focus on Pediatric Cardiac Patients.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Hamideh Abbaspour KasgariDepartment of Clinical Pharmacy, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Siavash MoradiEducation Development Center, Mazandaran University of Medical Sciences, Sari, Iran.
Amir Mohammad ShabaniDepartment of Clinical Pharmacy, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Farhang BabamahmoodiAntimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Ali Reza Davoudi BadabiAntimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Lotfollah DavoudiAntimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Ahmad AlikhaniAntimicrobial Resistance Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Akbar Hedayatizadeh OmranGastrointestinal Cancer Research Center, Cancer Research Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Majid SaeediPharmaceutical Sciences Research Center, Hemoglobinopathy Research Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Shahin MeratLiver and Pancreatobiliary Diseases Research Center, Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Hannah WentzelSchool of Public Health, Imperial College London, London, UK.
Anna GarrattCardiff and Vale University Health Board, Cardiff, UK.
Jacob LeviAccident and Emergency Department, Homerton University Hospital NHS Trust, London, UK.
Bryony SimmonsDepartment of Infectious Disease, Imperial College London, London, UK.
Andrew HillDepartment of Translational Medicine, University of Liverpool, UK.
Hafez Tirgar FakheriGut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
Mazandaran University of Medical Sciences · IRImperial College London · GBCardiff and Vale University Health Board · GBHomerton University Hospital · GBTehran University of Medical Sciences · IRUniversity of Liverpool · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNew therapeutic options are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19). Repurposing existing pharmaceuticals provides an immediate treatment opportunity. We assessed the efficacy of sofosbuvir and daclatasvir with ribavirin for treating patients with COVID-19.

methodsThis was a single-centre, randomized controlled trial in adults with moderate COVID-19 admitted to the Ghaem Shahr Razi Hospital in Mazandaran Province, Iran. Patients were randomly assigned to 400 mg sofosbuvir, 60 mg daclatasvir and 1200 mg ribavirin (intervention group) or to standard care (control group). The primary endpoint of this study was length of hospital stay. This study is registered by IRCT.ir under the ID: IRCT20200328046886N1.

resultsBetween 20 March 2020 and 8 April 2020, 48 patients were recruited; 24 patients were randomly assigned to the intervention group and 24 to the control group. The median duration of hospital stay was 6 days in both groups (P = 0.398). The number of ICU admissions in the sofosbuvir/daclatasvir/ribavirin group was not significantly lower than the control group (0 versus 4, P = 0.109). There was no difference in the number of deaths between the groups (0 versus 3, P = 0.234). The cumulative incidence of recovery was higher in the sofosbuvir/daclatasvir/ribavirin arm (Gray's P = 0.033).

conclusionsThis randomized trial was too small to make definitive conclusions. There were trends in favour of the sofosbuvir/daclatasvir/ribavirin arm for recovery and lower death rates. However, there was an imbalance in the baseline characteristics between the arms. Larger randomized trials should be conducted to investigate this treatment further.

Indexed as

BetacoronavirusAdultAgedAntiviral AgentsCarbamatesCoronavirus InfectionsCOVID-19Drug Therapy, CombinationFemaleHospitalizationHumansImidazolesIranMaleMiddle AgedPandemicsAntiviral AgentsCarbamatesdaclatasvirImidazolesPyrrolidinesRibavirinSofosbuvirValine

Identifiers

PMID32812025
PMCPMC7454669
OpenAlexW3060275525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.